

7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA **Telephone:** +1-925-399-1568 **E-mail:** office@baishideng.com https://www.wjgnet.com

PEER-REVIEW REPORT

Name of journal: World Journal of Gastrointestinal Surgery

Manuscript NO: 89900

Title: Ex-vivo liver resection auto-transplantation and special systemic therapy in

perihilar cholangiocarcinoma treatment

Provenance and peer review: Invited Manuscript; Externally peer reviewed

Peer-review model: Single blind

Reviewer's code: 03881243 Position: Editorial Board Academic degree: MD, PhD

Professional title: Associate Chief Technician, Deputy Director, Professor

Reviewer's Country/Territory: China

Author's Country/Territory: Russia

Manuscript submission date: 2023-11-16

Reviewer chosen by: AI Technique

Reviewer accepted review: 2023-11-30 04:13

Reviewer performed review: 2023-12-05 15:19

Review time: 5 Days and 11 Hours

	[] Grade A: Excellent [Y] Grade B: Very good [] Grade C:
Scientific quality	Good
	[] Grade D: Fair [] Grade E: Do not publish
Novelty of this manuscript	[] Grade A: Excellent [Y] Grade B: Good [] Grade C: Fair [] Grade D: No novelty
Creativity or innovation of	[] Grade A: Excellent [Y] Grade B: Good [] Grade C: Fair
this manuscript	[] Grade D: No creativity or innovation



7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA **Telephone:** +1-925-399-1568 **E-mail:** office@baishideng.com https://www.wjgnet.com

Scientific significance of the conclusion in this manuscript	[] Grade A: Excellent [Y] Grade B: Good [] Grade C: Fair [] Grade D: No scientific significance
Language quality	[] Grade A: Priority publishing [Y] Grade B: Minor language polishing [] Grade C: A great deal of language polishing [] Grade D: Rejection
Conclusion	[] Accept (High priority) [] Accept (General priority) [Y] Minor revision [] Major revision [] Rejection
Re-review	[]Yes [Y]No
Peer-reviewer statements	Peer-Review: [Y] Anonymous [] Onymous Conflicts-of-Interest: [] Yes [Y] No

SPECIFIC COMMENTS TO AUTHORS

Comments: 1. This editoral describes the application of ELRAT in perihilar cholangiocarcinoma, while clinical doctor confuse to choose beneficial populations. The Editorial need to be made in the review. 2. The fifth paragraph of the second part is a bit too long for the outcome of the article mentioned, which could add to the discussion and summary. 3. The fourth paragraph of Part Two refers to "higher morbidity", but not in the following paragraphs. 4. "Munugala et al added to FGFR the Isocitrate dehydrogenase (IDH) mutations accounted up to 15% in different subsets of CCA" The meaning of the number 15% in this sentence is unclear. 5. The editorial should add more comments on the article by Hu et al. 6. Explain the abbreviations that appear for the first time in the article, such as "CCA", "LT", "ERAT".